H uman atherosclerosis has been associated with variants of the gene KALRN in several independent human cohorts, [1] [2] [3] yet the function of the proteins encoded by KALRN-Kalirin isoforms-has been studied almost exclusively in neurons and pituitary cells. The most abundantly expressed Kalirin isoform outside the central nervous system is Kalirin-9, for which mRNA is detectable in aorta, liver, and skeletal muscle of adult mice. 4 A 270-kDa protein, Kalirin-9 is one of only 2 mammalian proteins that contain 2 GDP/GTP exchange factors (GEFs) for the Rho family GTPases, which are critical for cytoskeletal dynamics and consequently for cell motility and proliferation. 5 Phylogenetic conservation from C. elegans to human attests to the importance of Kalirin-9 in cell biology. 6 Kalirin-9 comprises an N-terminal phospholipid-binding Sec14p domain followed by 9 spectrin repeats, its RhoGEF1 domain, a Src-homology 3 (SH3) domain, its RhoGEF2 domain, and a second SH3 domain ( Figure 1A ). 6 Whereas the RhoGEF1 domain of Kalirin activates Rac1 and RhoG, the RhoGEF2 domain activates RhoA. 6 The spectrin repeats are known thus far to bind to the N-terminal region of inducible nitric oxide synthase (NOS2), 7 to peptidylglycine α-amidating monooxygenase, Huntingtin-associated protein-1, Disrupted-in-Schizophrenia 1, Arf6, sorting nexins 1 and 2, and αII-spectrin. 6, 8 Kalirin has one mammalian ortholog, named Trio, with which Kalirin shares 65% to 85% amino acid identity in the RhoGEF domains. 6 Nevertheless, Kalirin and Trio are not interchangeable: Trio -/-and Kalrn -/-mouse embryos die during development on the 129/C57BL/6 mixed genetic background, 4, 6 and Kalrn -/-mice show diminished size and multiple abnormalities on the C57BL/6 background. 4 
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Kalirin's RhoGEF activity could plausibly augment atherogenesis by enhancing vascular smooth muscle cell (SMC) proliferation and migration, [9] [10] [11] and endothelial dysfunction, 12 among other mechanisms. Of the 60 to 70 RhoGEFs encoded by mammalian genomes, 13 27 are expressed as mRNAs in SMCs, 14 but only a third of these have been shown to serve unique functions in SMCs. [14] [15] [16] [17] [18] [19] By activating Rac1 in SMCs, Kalirin's RhoGEF1 activity could promote SMC migration and proliferation by activating the p21-activated (Ser/Thr) kinase (PAK), [20] [21] [22] and NADPH oxidases. 23 By activating RhoA, Kalirin's RhoGEF2 activity could promote not only SMC migration and proliferation, 24 but also endothelial dysfunction 12 -through the action of the Rho-associated coiled-coil-containing protein (Ser/Thr) kinases. We sought to test the hypothesis that Kalirin-9 functions as a dual Rho-GEF in SMCs, and thereby promotes SMC activation in vitro and in vivo. To do so, we used primary aortic SMCs from wild-type (WT) and congenic Kalrn -/+ mice, as well as wire-mediated carotid endothelial denudation injury in WT and congenic Kalrn -/+ mice.
Materials and Methods
Materials and methods are available in the online-only Supplement.
Results

Vascular Expression of Kalirin
To delineate potential loci of Kalirin activity in vascular biology, we first immunoblotted mouse tissues and cells to determine their Kalirin-expression levels relative to those obtained in mouse brain. As Figure 1B shows, primary SMCs, endothelial cells, and macrophages all express Kalirin-9 at levels comparable with those obtained from mouse brain, and similar findings were obtained by using extracts from mouse aorta or bone marrow. In contrast, aortas from Kalrn -/-mice demonstrated no immunoreactivity corresponding to Kalirin-9 ( Figure 1C ). To determine whether Kalirin expression changed in the context of atherogenesis, we compared thoracic aortas from WT and Apoe -/-mice aged 8 weeks, before intimal macrophage infiltration occurs. 25 Kalirin-9 protein expression was 1.6±0.2-fold higher in aortas from Apoe -/-than from WT mice (P<0.05; Figure 1C ). Thus, vascular cell expression of Kalirin-9 is upregulated during the earliest stages of atherogenesis.
Kalirin Activates Rac1 in SMCs
To test whether Kalirin function affects SMC physiology, we first inhibited Kalirin's RhoGEF1 domain by treating primary SMCs with the cell-permeant compound NPPD (1-(3-nitrophenyl)-1H-pyrrole-2,5-dione), which selectively inhibits GDP/GTP exchange activity promoted by the highly homologous RhoGEF1 domains of Kalirin and its lone ortholog, Trio. 26 Kalirin's RhoGEF1 and RhoGEF2 domains activate Rac1 and RhoA, respectively ( Figure 1A) . 6 We therefore assessed SMC Rac1 and RhoA activity, by determining the activity of their respective effector kinases: PAK1, which when activated by Rac1-GTP autophosphorylates on Thr-423; 27 and Rho-associated coiled-coil-containing protein kinases (ROCK1, ROCK2), which when activated by RhoA-GTP phosphorylate the myosin phosphatase-targeting subunit 1 (MYPT1) on Thr-853. 28 PAK1 autophosphorylation induced by platelet-derived growth factor (PDGF) was reduced by 40±20% (P<0.05) in SMCs treated with NPPD (Figure 2A and 2B ). In contrast, (ROCK-mediated) MYPT1 phosphorylation was not affected by NPPD (Figure 2A and 2B) Figure 2C ). Consequently, we inferred that most of the NPPD-inhibited, PDGF-induced Rac-GEF activity in SMCs is attributable to Kalirin, rather than to Trio.
To complement NPPD-mediated inhibition of Kalirin's RhoGEF1 domain, and to determine whether Kalirin's RhoGEF2 domain is also important in SMC physiology, we used Kalirin RNAi. Relative to SMCs transfected with control small interfering RNA, SMCs transfected with Kalirintargeting small interfering RNA demonstrated 43±9% less Kalirin protein expression and 50±20% less PAK1 autophosphorylation in response to PDGF or serum (P<0.05; Figure 2D -2F). Nevertheless, Kalirin knockdown SMCs demonstrated MYPT1 phosphorylation (evidence of ROCK activity) 28 that was equivalent to control SMCs ( Figure 2E  and 2F ). Thus, we obtained equivalent results in SMCs with Kalirin knockdown and chemical inhibition of Kalirin's RhoGEF1 domain, and Kalirin appears to function in SMCs as an important GEF for Rac1, but not for RhoA.
To corroborate these data obtained with Kalirin RNAi, we used 5 independently isolated lines of SMCs from age-and sex-matched Kalrn -/+ and littermate WT mice. Kalrn -/+ SMCs expressed only 45±5% as much Kalirin-9 protein as WT SMCs, but equivalent levels of proteins critical for the receptor tyrosine kinase and (heterotrimeric) G q/11 signal transduction pathways under investigation: PDGF receptor-β, endothelin receptor type A, Rac1, RhoA, PAK1, and MYPT1 ( Figure 3A ).
When stimulated with serum, PDGF, or endothelin-1, Kalrn -/+ SMCs demonstrated only ≈60% of WT PAK1 activation, as assessed by PAK1 autophosphorylation ( Figure 3B and 3C). In contrast, Kalrn -/+ SMCs demonstrated WT levels of ROCK activation, as assessed by MYPT1 phosphorylation 28 ( Figure  3B and C). Because ROCK isoforms can be activated not only by RhoA (the target of Kalirin's RhoGEF2 domain), but also by RhoB and RhoC, 29 we also assessed SMC RhoA-GTP levels. Consistent with MYPT1 phosphorylation data, Kalrn
and WT SMCs demonstrated equivalent, 2-to 3-fold over basal stimulation of RhoA-GTP loading in response to serum ( Figure 3D ). In contrast, Kalrn -/+ SMCs demonstrated 30% less Rac1-GTP loading than WT SMCs ( Figure 3D ). Thus, assessed at the level of the GTPase or the effector kinases, Kalirin appears to promote the activation of Rac1, but not RhoA, in SMCs.
Kalirin Promotes SMC Migration and Proliferation
Because Rac1 and PAK1 signaling are critical for SMC migration, 20, 21 we reasoned in light of Figure 3 that loss of Kalirin function would reduce SMC migration. To test this hypothesis, we studied SMC migration in modified Boyden chambers. Stimulus-independent SMC migration was not affected by loss of Kalirin function (Figure 4) . However, whether engendered by chemical inhibition of Kalirin's RhoGEF1 domain (by NPPD), by Kalirin RNAi, or by Kalirin haploinsufficiency, loss of Kalirin function was associated with a ≈35% reduction in PDGF-or serumevoked SMC migration (P<0.05; Figure 4 ). To determine whether loss of Kalirin function reduced SMC migration principally by reducing Rac1 activation, we treated SMCs with the cell-permeant Kalirin RhoGEF1 inhibitor ITX3 34 or the Rac1 inhibitor Z62954982, using conditions that have been shown to inhibit PDGF-induced GTP loading of Rac1 by ≈50% without affecting GTP loading of the related Rho-GTPases Cdc42 or RhoA. 35 Kalirin RhoGEF1 or Rac1 inhibition with ITX3 or Z62954982, respectively, reduced by 35% to 40% the migration of WT SMCs stimulated by PDGF ( Figure 4D ). This attenuation of SMC migration was comparable with that seen with the loss of Kalirin function observed in Kalrn -/+ SMCs. Furthermore, the impaired migration of Kalrn -/+ SMCs was not further reduced by ITX3 or Z62954982 ( Figure 4D ). In parallel experiments with WT SMCs, Z62954982 inhibited PAK1 autophosphorylation by 40±10%, but neither ITX3 nor Z62954982 inhibited ROCK activity, manifest as MYPT1 phosphorylation, or mitogenactivated or extracellular signal-regulated protein kinase kinase-1 activity, manifest as phosphorylation of extracellular signal-regulated kinase-1 and -2 ( Figure 4E and data not shown). As a further demonstration of inhibitor specificity, neither ITX3 nor Z62954982 reduced the SMC migration promoted by fetal bovine serum under the conditions prevailing in these experiments ( Figure 4D ). Taken together, these data suggest that Kalirin mediates Rac1 activation in SMCs downstream of the PDGF receptor, and thereby promotes SMC migration.
Whereas cellular migration can be promoted by Rac1 activity at the plasma membrane, 20 cellular proliferation appears to require Rac1 nuclear localization. 32 Thus, despite SMCs proliferated 50% less rapidly than WT SMCs in response to serum (P<0.03; Figure 5 ). Thus, Kalirin appears to promote SMC proliferation.
SMC Kalirin Promotes Neointimal Hyperplasia
SMC proliferation and migration are fundamental to the neointimal hyperplasia that develops in response to arterial endothelial denudation. 24 If Kalirin's positive effects on SMC migration and proliferation occurred not only in vitro, but also in vivo, we reasoned that Kalrn -/+ mice should develop less neointimal hyperplasia than WT mice. We therefore provoked carotid artery neointimal hyperplasia in congenic Kalrn -/+ and WT mice by denuding the endothelium with a 0.36-mm wire-an approach that we have shown engenders neointimal hyperplasia comprising only SMCs from the arterial media. 24 Neointimal SMCs ( Figure Kalrn -/+ mice developed 60% less neointima than WT mice ( Figure 6 and Figure I in the online-only Data Supplement). However, this result could have been produced by pleiotropic effects of Kalirin in endothelial cells or leukocytes. 33 We therefore sought to ascertain that SMC Kalirin activity, specifically, was promoting the in vivo SMC proliferation and migration of neointimal hyperplasia. To do so, we used mice with SMC-specific deletion of Kalrn (SMC-Kalrn -/+ mice expressed Kalirin-9 protein levels that were 50±5% less in endothelium-stripped aortas, but equivalent in whole-brain extracts ( Figure 6A ). After carotid endothelial denudation, SMC-Kalrn -/+ mice developed 65% less neointimal hyperplasia than in either control mouse cohort ( Figure  6B and 6C) . Before surgery, Kalrn -/+ , SMC-Kalrn -/+ , and WT mice had equivalent carotid dimensions (data not shown) and equivalent systolic blood pressures and heart rates: respectively, 121±7, 120±10, and 120±10 mm Hg; 700±40, 640±40, and 660±40 bpm (n=7/group). Thus, whether in SMCs alone or in combination with endothelial cells and leukocytes, Kalirin activity contributes to neointimal hyperplasia. 
Discussion
This study establishes Kalirin, a human atherosclerosis candidate gene, 1-3 as a significant signaling intermediate that promotes SMC Rac1 activation, migration, and proliferation downstream of the PDGF receptor-β and G protein-coupled receptors in vitro ( Figure VII in the online-only Data Supplement). Consonant with this signaling activity in SMCs, Kalirin in vivo promotes neointimal hyperplasia induced by arterial endothelial denudation-whether Kalirin expression is manipulated globally, or just in SMCs. It is noteworthy that Kalirin's role in vascular biology manifests with loss-offunction models that allow ≈50% of normal Kalirin activity. Consequently, the magnitude of Kalirin's total contribution to vascular pathophysiology may be underestimated by these models; nevertheless, incomplete loss-of-function models human disease and pharmacotherapeutic responses better than complete loss-of-function. [1] [2] [3] Kalirin-promoted SMC migration and proliferation correlate with Kalirin's Rac1-GEF activity, triggered by the PDGF receptor-β: indeed, Kalirin deficiency impaired SMC migration only when Rac1 activity was intact (Figure 4) . In neurons, Kalirin Rac-GEF activity is triggered by the receptor tyrosine kinase EphB2, which tyrosine-phosphorylates and recruits Kalirin to the plasma membrane. 34 Whether this method of Kalirin activation occurs downstream of the PDGF receptor-β tyrosine kinase remains to be established. However, SMCs express both EphB2 and its agonist ephrinB2, which appear to promote SMC migration in vivo; 35 thus, Kalirin could mediate SMC migration in vivo downstream of multiple receptor tyrosine kinases. Furthermore, because EphB2 receptors on monocytes promote adhesion to arteries and because monocyte/macrophages express abundant Kalirin (Figure 1) , it is conceivable that an EphB2-Kalirin signaling axis operates in monocytes to promote monocyte/macrophage infiltration of the (ephrinB2-expressing) 35 tunica media of injured arteries. Because monocyte/macrophages contribute significantly to neointimal hyperplasia, 36 Kalirin deficiency in monocytes could thus contribute to the reduction in neointimal hyperplasia we observed in Kalrn -/+ as compared with WT mice (Figure 6 ).
Despite containing a GEF domain specific for Rac1 and a GEF domain specific for RhoA, 6 Kalirin appears to function in SMCs as a GEF only for Rac1, and not for RhoA. This inference is based on comparisons among SMCs with Kalirin levels that were either 100% or ≈50% of WT; consequently, it may be that 50% of normal Kalirin levels in SMCs suffice to drive normal activation of RhoA, but not Rac1. Alternatively, Kalirin's apparent Rho-family GTPase specificity in SMCs may result from distinct subcellular distributions, and overlapping functions of the myriad Rac1-and RhoA-GEFs expressed along with Kalirin in SMCs. [14] [15] [16] [17] [18] [19] Lastly, it is important to note that the overall GTPase activity reflects a balance between the activities of GEFs, which activate GTPases by promoting the exchange of GTP for GDP, and GTPase-activating proteins, which deactivate GTPases by enhancing hydrolysis of GTP to GDP. 5 Thus, it may be that the functionality of GTPaseactivating proteins for Rac1 exceeds that of GTPase-activating proteins for RhoA in SMCs; if so, we could ascertain differences in Kalirin-mediated activation of Rac1 more sensitively than we could for RhoA.
Kalirin may also contribute to neointimal hyperplasia through mechanisms distinct from its Rac1-GEF activity. For example, Kalirin's interaction with the N-terminal domain of NOS2 prevents NOS2 dimerization, and thereby inhibits NOS2 activity. 7 Perhaps because NOS2-produced NO· reduces SMC proliferation and mitochondrial respiration, 
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-/--mice develop more medial thickening than WT mice subjected to carotid endothelial denudation. 38 Consequently, by inhibiting SMC NOS2, Kalirin could reduce NO·-mediated inhibition of SMC proliferation-and thereby contribute to neointimal hyperplasia. Whether such a mechanism occurs in SMCs remain to be established.
Achieved either genetically or by RNAi, just a 50% reduction in Kalirin activity suffices to reduce SMC proliferation and migration in vitro and in vivo. Consequently, Kalirin appears to be an appealing target for pharmacotherapy in SMC-proliferative disorders like neointimal hyperplasia. Because interventions that diminish neointimal hyperplasia often diminish atherosclerosis, too, 24, 39 the work presented here adds credence to human genetic data [1] [2] [3] implicating Kalirin in atherogenesis. Direct evidence to support Kalirin's role in atherosclerosis, of course, has yet to manifest. 
Sources of Funding
